Erectile Dysfunction Drugs Market Growth

Erectile Dysfunction Drugs Market Research, 2030

Erectile Dysfunction Drugs Market to surpass USD 5.9 million by 2030 from USD2.68 million in 2020 at a CAGR of 8.3% in the coming years, i.e., 2021-30.

Inability to maintain and develop an erection for satisfactory sexual intercourse or activity refers to erectile dysfunction. The main causes of erectile dysfunction are high blood pressure, diabetes, high cholesterol, or depression. The symptoms of erectile dysfunction include trouble in maintaining an erection, difficulty in achieving an erection, and a reduced interest in sex. There are many medications available to treat erectile dysfunction which are commonly known as erectile dysfunction drugs. Sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) are some of the oral medications that reverse erectile dysfunction by improving the effects of nitric oxide, a natural chemical that a body produces that relaxes the muscles of the penis. This increases blood flow and allows them to get an erection in response to sexual stimulation.

Market Highlights

The global Erectile Dysfunction Drugs Market is expected to project a notable CAGR of 8.3% in 2030.

Global Erectile Dysfunction Drugs Market to surpass USD 5.9 million by 2030 from USD 2.68 million in 2020 at a CAGR of 8.3% in the coming years, i.e., 2021-30. Due to the rising healthcare expenditure on sexual wellness, the demand for erectile dysfunction drugs is experiencing an escalating demand. The development of novel drug formulations is propelling the market growth further. Additionally, there is a high demand for these drugs from the elderly population as they have hormonal imbalances such as a reduction in libido which is also contributing to the growth of the erectile dysfunction market.

Recent Highlights in Global Erectile Dysfunction Drugs Market

In October 2018, Teva Pharmaceutical launched a generic version of Cialis in the U.S., which is used for the treatment of erectile dysfunction.
In May 2017, Lupin Ltd. launched Cialis, an erectile dysfunction drug through a licensing agreement with Eli Lilly and Company. With this alliance, Eli Lilly will be responsible for manufacturing and importing the product.

Global Erectile Dysfunction Drugs Market: Segments

Viagra (sildenafil citrate) segment to grow with the highest CAGR during 2021-30

The global Erectile Dysfunction Drugs market is segmented by drug type into Viagra (sildenafil citrate), Cialis (Tadalafil), and Staxyn/Levitra (vardenafil), Stendra/Spedra (avanafil), Zydena (udenafil), Vitaros (Alprostadil Cream), and Others. Viagra (sildenafil citrate), the segment held the largest market share of XX.X% in the year 2020 owing to its large number of sales worldwide over other drugs. Due to its longer duration of action and lesser incidences of adverse effects such as vision problems and muscle pain, it is preferred over other drugs.

Oral Medications segment to grow with the highest CAGR during 2021-30

The global Erectile Dysfunction Drugs market is divided by Mode of Administration into Oral Medications, Topical Medications, Injections, and Others. Oral Medications, the segment held the largest market share of XX.X% in the year 2020 and will continue to dominate the market in the coming years. Oral medications have several advantages including easy absorption, safety, good patient compliance, versatility, and pain avoidance owing to which it is preferred over other routes of administration.

Retail Pharmacies segment to grow with the highest CAGR during 2021-30

The global Erectile Dysfunction Drugs market is divided by Distribution channels into Hospital Pharmacies, Retail Pharmacies, and Online Sales. Retail Pharmacies, the segment held the largest market share of XX.X% in the year 2020 and will continue to dominate the market in the coming years as erectile dysfunction drugs are easily available at these stores. Both urban and rural consumers have access to retail pharmacies.

Market Dynamics

Drivers

Increasing adoption of the sedentary lifestyle

The rising adoption of a sedentary lifestyle is resulting in the high growth of obesity, cardiovascular diseases, and diabetes, leading to complications such as erectile dysfunction. Poor lifestyle choices, smoking, and alcoholism increase the risk of erectile dysfunction which in turn is boosting the overall growth of the erectile dysfunction drug market. Besides, the factors such as the rise in the geriatric population and life expectancy are also driving the demand for erectile dysfunction drugs.

Development of new drug formulations

Many firms in the erectile dysfunction drugs industry are introducing new drug delivery methods such as the use of pellets and creams. In treating erectile dysfunction, pellets and creams can have more effectiveness and enhanced performance, and they are both more effective and safer to use. Furthermore, the advent of novel formulations including injectable and topical gels is anticipated to proliferate the market in the coming years. As an alternative to oral tablets, these formulations are estimated to attract a large number of patients.

Restraint

Side effects of drugs on health

The consumption of erectile dysfunction drugs may harm health which is likely to impede the market growth. The common side effects include headache, nasal congestion, vision problems, dizziness, and diarrhea. Moreover, patients with cardiovascular disease have more risk as these drugs can cause a drop in blood pressure.

Global Erectile Dysfunction Drugs Market: Key Players

Apricus Biosciences Inc

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

Bayer AG
Cristalia Dong-A Pharmaceutical Co. Ltd.
Produtos Quimicos Farmaceuticos Ltd.
Eli Lilly and Company
Pfizer, Inc.
GlaxoSmithKline Plc
S.K. Chemicals Co. Ltd.
Meda Pharmaceuticals, Inc
Vivus, Inc.
Metuchen Pharmaceuticals LLC
Other Prominent Players

Global Erectile Dysfunction Drugs Market: Regions

The global Erectile Dysfunction Drugs Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. Global Erectile Dysfunction Drugs Market in North America held the largest market share of XX.X% in the year 2020. North America will continue to dominate the global Erectile Dysfunction Drugs market owing to rising healthcare expenditure, growing geriatric population, and high life expectancy. Also, increasing consumer awareness and education in the region is anticipated to fuel the growth of the market.

Global Erectile Dysfunction Drugs Market is further segmented by region into:

North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – the United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
the Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

The global Erectile Dysfunction Drugs Market report also contains an analysis on:

Erectile Dysfunction Drugs Market Segments:

By Drug type
- Viagra (sildenafil citrate)
- Cialis (Tadalafil)
- Staxyn/Levitra (vardenafil)
- Stendra/Spedra (avanafil)
- Zydena (udenafil)
- Vitaros (Alprostadil Cream)
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
By Mode of Administration
- Oral Medications
- Topical Medications
- Injections
- Others
Erectile Dysfunction Drugs Market Dynamics
Erectile Dysfunction Drugs Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints

Frequently Asked Questions (FAQ):

Market is growing due to an ageing male population, higher incidence of lifestyle-related health conditions such as diabetes and cardiovascular disease, and improved awareness and acceptance of ED treatment.

Phosphodiesterase type 5 (PDE5) inhibitors remain the dominant drug class for treating ED, accounting for the largest portion of the market revenue.

Oral tablets are the preferred mode because they offer convenience, non-invasive administration and broad patient acceptance compared with injections or topical formats.

Digital health platforms and online pharmacies are expanding access and convenience for ED treatments, reducing barriers of stigma and geography, and thus contributing to market growth.